Techniclone (TCLN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roland Ott who wrote (1029)	1/8/1998 12:42:00 PM
From: EZLibra	Read Replies (1) of 3702

Hello Switzerland! Simply explained, Antiangiogenesis by TCLN debulks the primary solid tumor. It blocks the blood vessels of the tumor's vascular system that feed it, thereby killing it. Antiangiogenesis by ENMD treats metastatic cancers, which are the non-primary tumors, by shrinking the blood vessels that feed the cancer. The tumors still exist but are undernourished. Both therapies are in animal studies. There is a great deal of direct competition for ENMD and no direct competition for TCLN. You might wish to read post # 822. Know anyone at the Paul Scherer (sp) Institute?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next